Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Neuropsychopharmacol Rep ; 42(2): 166-173, 2022 06.
Article in English | MEDLINE | ID: mdl-35174671

ABSTRACT

AIM: To investigate the association between psychotropic prescriptions and the total amount of psychotropics ingested during a subsequent intentional overdose and to examine factors related to the number of psychotropic prescriptions. METHODS: The initial sample comprised 69 patients who were admitted to the emergency department of a general hospital in Japan following an intentional overdose via psychotropic medications. We performed retrospective hierarchical multiple regression analysis with the total amount of psychotropics ingested at the overdose as a dependent variable and factors related to deliberate self-harm or overdose identified in previous studies as independent variables. We compared two models, one that did not (Step 1) and one that did (Step 2) include the number of different prescribed psychotropic medications as an independent variable in the analysis. RESULTS: Forty-seven patients were eligible for the analysis. The number of different prescribed psychotropic medications was associated with the total amount of psychotropics ingested at the overdose in Step 2 (ß = 0.40, P = .01). There was a trend toward an association between the past number of deliberate self-harm events and the total amount of psychotropics ingested at the overdose in Step 1 (ß = 0.30, P = .05), but this trend was weakened in Step 2 (ß = 0.15, P = .33). CONCLUSION: The number of different prescribed psychotropics appeared to influence the risk of subsequent intentional overdose through increasing the total amount of psychotropics ingested. Cumulative psychotropic prescriptions, particularly those delivered after deliberate self-harm, might be indirectly related to this risk.


Subject(s)
Drug Overdose , Drug Prescriptions , Drug Overdose/epidemiology , Humans , Japan/epidemiology , Psychotropic Drugs , Retrospective Studies
2.
Am J Alzheimers Dis Other Demen ; 35: 1533317520904551, 2020.
Article in English | MEDLINE | ID: mdl-32052640

ABSTRACT

This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (n = 10) or amyloid-negative (n = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.


Subject(s)
Alzheimer Disease/diagnosis , Amyloid beta-Peptides/metabolism , Cognitive Dysfunction/diagnostic imaging , Disclosure , Healthy Volunteers/statistics & numerical data , Aged , Anxiety/psychology , Depression/psychology , Female , Humans , Longitudinal Studies , Male
3.
Psychogeriatrics ; 19(4): 325-332, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30688000

ABSTRACT

BACKGROUND: Subjective cognitive decline (SCD) may herald the first symptoms of Alzheimer's disease (AD) whereas individuals with beta-amyloid (Aß) deposition are regarded as a high-risk group for AD. Recently, amyloid positron emission tomography (PET) studies have demonstrated clinical and cognitive feature differences between Aß-positive and negative SCD, but details of their differences remain unclear. We aimed to investigate the relationships among Aß deposition, clinical, and cognitive features in patients with SCD. METHODS: Forty-two patients with SCD (22 women, 74.5 ± 4.7 years) were examined using fluorine-18 florbetaben PET and were divided into Aß-positive (n = 10) and negative (n = 32) groups. We compared cognitive and psychological outcomes, and single photon emission computed tomography (SPECT) imaging data between the two groups. In addition, a linear regression analysis was performed to assess relationships between the severity of SCD and neuropsychological tests, affective scores, and demographic factors. RESULTS: The rate of score changes from the immediate recall to delayed recall in the logical memory subtest of the Wechsler's Memory Scale Revised were different between the groups (P = 0.04). However, the binary logistic regression analysis showed no significant differences between the two. In addition, the severity of SCD was significantly strong in women (P = 0.002). Furthermore, within the Aß-negative group, subjective memory loss correlated with word fluency category score (P = 0.023) and apathy scale (P = 0.037). CONCLUSIONS: No significant differences were observed between Aß-positive and -negative SCD on any of the neuropsychological measures, clinical measures, or SPECT imaging. Further, the severity of SCD was not predicted by the symptoms of anxiety, depression, or neuropsychological examination.


Subject(s)
Amyloid beta-Peptides/metabolism , Cerebrovascular Circulation/physiology , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/physiopathology , Memory Disorders/metabolism , Memory Disorders/physiopathology , Aged , Aged, 80 and over , Aniline Compounds , Cognitive Dysfunction/diagnostic imaging , Diagnostic Self Evaluation , Female , Humans , Male , Memory Disorders/diagnostic imaging , Positron-Emission Tomography , Severity of Illness Index , Stilbenes , Tomography, Emission-Computed, Single-Photon
4.
Int Psychogeriatr ; 30(5): 635-639, 2018 05.
Article in English | MEDLINE | ID: mdl-29094656

ABSTRACT

ABSTRACTIn Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-ß (Aß) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aß positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aß positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aß positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aß PET results to asymptomatic Japanese adults with SCD was indicated.


Subject(s)
Alzheimer Disease/diagnostic imaging , Alzheimer Disease/psychology , Brain/diagnostic imaging , Disclosure/ethics , Positron-Emission Tomography/adverse effects , Aged , Aged, 80 and over , Amyloid beta-Peptides/analysis , Anxiety/etiology , Depression/etiology , Female , Humans , Japan , Male , Neuropsychological Tests , Positron-Emission Tomography/ethics
5.
Neuropsychiatr Dis Treat ; 13: 17-24, 2017.
Article in English | MEDLINE | ID: mdl-28031714

ABSTRACT

BACKGROUND: Despite available treatments, major depression is a highly heterogeneous disorder, which leads to problems in classification and treatment specificity. Previous studies have reported that personality traits predict and influence the course and treatment response of depression. The Temperament and Personality Questionnaire (T&P) assesses eight major constructs of personality traits observed in those who develop depression. The aim of this study was to investigate the influence of T&P's eight constructs on the treatment outcome of depressed patients. PATIENTS AND METHODS: A preliminary 6-month prospective study was conducted with a sample of 51 adult patients with a diagnosis of major depressive disorder (MDD) without remarkable psychomotor disturbance using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. All patients received comprehensive assessment including the T&P at baseline. We compared each T&P construct score between patients who achieved remission and those who did not achieve remission after 6 months of treatment for depression using both subjective and objective measures. All 51 (100%) patients received the 6-month follow-up assessment. RESULTS: This study demonstrated that higher scores on T&P personal reserve predicted poorer treatment outcome in patients with MDD. Higher levels of personal reserve, rejection sensitivity, and self-criticism correlated with higher levels of depression. Higher levels of rejection sensitivity and self-criticism were associated with non-remitters; however, when we controlled for baseline depression severity, this relationship did not show significance. CONCLUSION: Although the results are preliminary, this study suggests that high scores on T&P personal reserve predict poorer treatment outcome and T&P rejection sensitivity and self-criticism correlate with the severity of depression. Longer follow-up studies with large sample sizes are required to improve the understanding of these relationships.

SELECTION OF CITATIONS
SEARCH DETAIL
...